Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES

v3.20.2
ACCRUED EXPENSES
 9 Months Ended
Sep. 30, 2020
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

 

8. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

 Schedule of Accrued Expenses

    September 30, 2020     December 31, 2019  
             
Accrued clinical operations and trials costs   $ 18,709,059     $ 14,242,669  
Accrued product development costs     3,589,136       3,573,231  
Accrued compensation     4,676,027       3,673,111  
Accrued other     1,618,827       958,928  
Total   $ 28,593,049     $ 22,447,939